Skip to main content
Premium Trial:

Request an Annual Quote

Claremont BioSolutions Lands UK, Ireland Distributor for Sample Prep Products


This article was originally published on Dec. 5.

Claremont BioSolutions said today that it has reached an agreement with Bioquote Limited to distribute in the UK and Ireland its products for cell lysis, DNA extraction and isolation, and His-tagged protein purification.

Claremont said that the distribution agreement extends its reach into European markets.

Based in Upland, Calif., Claremont specializes in disposable devices for improving sample prep in DNA diagnostics. The company's proprietary devices use micromotors to perform mechanical cell lysis and DNA purification. These devices prepare samples for DNA analysis in less than five minutes and without any extraneous instruments, and can be easily incorporated into sample-to-answer and lab-on-a-chip cartridges for point-of-care nucleic acid testing, the company said.

The first products to be marketed under the agreement will be Claremont's Omnilyse lysis kits and PureLyse DNA extraction kits.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.